Risk was increased with neurofilament levels higher than in controls.
Plasma neurofilament (pNfL) is a marker of axonal integrity and corresponds to treatment outcomes in patients with multiple sclerosis (MS). Long-term outcome was investigated in 4385 people with MS and 1026 healthy participants (controls).
Baseline median pNfL was 11.4 pg/mL in patients with MS and 7.5 pg/mL in healthy controls. Median follow-up was 5 years. For pNfL levels at about the 80th percentile of controls' levels (C80) compared with lower levels, the hazard ratio for reaching Expanded Disability Status Scale (EDSS) score 3.0 was 1.49 (95% confidence interval, 1.23–1.81). Similar results were obtained for progression to EDSS 4.0 and 6.0. For patients with C80, the hazard ratio for EDSS worsening in the year after sampling was 1.40 (9…
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)